In yesterday’s Wall Street session, Candel Therapeutics Inc (NASDAQ:CADL) shares traded at $9.80, up 26.45% from the previous session.
CADL stock price is now 83.20% away from the 50-day moving average and 65.46% away from the 200-day moving average. The market capitalization of the company currently stands at $318.27M.
With the price target of $11, H.C. Wainwright recently initiated with Buy rating for Candel Therapeutics Inc (NASDAQ: CADL). On November 19, 2021, BMO Capital Markets recently initiated its ‘Outperform’ rating on the stock quoting a target price of $18, while ‘UBS’ rates the stock as ‘Buy’
In other news, Tyagarajan Seshu, Chief Technology Officer sold 20,392 shares of the company’s stock on Nov 29 ’24. The stock was sold for $92,898 at an average price of $4.56. Upon completion of the transaction, the Chief Technology Officer now directly owns 125,657 shares in the company, valued at $1.23 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Nov 29 ’24, Chief Executive Officer Tak Paul Peter sold 48,847 shares of the business’s stock. A total of $222,527 was realized by selling the stock at an average price of $4.56. This leaves the insider owning 294,788 shares of the company worth $2.89 million. A total of 37.53% of the company’s stock is owned by insiders.
During the past 12 months, Candel Therapeutics Inc has had a low of $1.00 and a high of $14.60. The fifty day moving average price for CADL is $5.2895 and a two-hundred day moving average price translates $5.882775 for the stock.
The latest earnings results from Candel Therapeutics Inc (NASDAQ: CADL) was released for 2024-06-30. The company reported revenue of $8.76 million for the quarter, compared to $8.86 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -1.17 percent.
